Testing effectiveness (Phase 2)Active Not RecruitingNCT06946797
What this trial is testing
Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 76